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A highly cationic protein in plasma and urine of children with steroid-
responsive nephrotic syndrome. We postulated that the reduction of
surface negative charge on the glomerular capillary wall, which is
believed to underlie the proteinuria of steroid-responsive nephrotic
syndrome (SRNS), might be due to the presence of a cationic substance
which binds to and neutralizes the negative charge on cells and
membranes. Using a method to detect charge neutralizing substances
based on inhibition of binding of the cationic dye Alcian blue 8GX to
heparin, plasma and urine from children with SRNS were found to
contain a protease-sensitive charge-neutralizing factor, which was not
present in plasma or urine of healthy individuals. This factor has been
partially purified from SRNS plasma and urine by ion exchange
chromatography on QAB Sephadex, gel filtration on Sephadex GISO,
and FPLC on Mono-S. This cationic protein, which binds to and
neutralizes the charge on heparin, may also neutralize the negative
charge on the glomerular capillary wall and may thus be involved in the
pathogenesis of SRNS.
The normal glomerulus functions as both a size and a charge
selective filter restricting the passage of negatively charged
macromolecules to a greater extent than those with neutral or
positive charge [1—5]. The physiochemical basis for this charge-
selective filtration is thought to be an electrostatic repulsion
between the fixed negative charge present on all layers of the
glomerular capillary wall (GCW), and the negative charge
present at physiological pH on albumin and many other plasma
proteins [1, 2, 5, 6]. The fixed negative charge on the GCW has
been consistently demonstrated by histochemical staining with
cationic probes [6—10], and its role in restricting the passage of
anionic macromolecules defined using a variety of charged
markers [4, 5, 9, 10]. Although sialic acid residues were
originally believed to be the chemical constituent responsible
for GCW negative charge [7, 8, 11, 12], it is now apparent that
the anionic glycosaminoglycans heparan sulphate and chon-
droitin sulphate are largely responsible [2, 13—15].
There is now substantial evidence that a reduction in the
surface negative charge on the GCW may underlie the protein-
uria of the steroid responsive nephrotic syndrome (SRNS),
Studies in both adults [16] and children [17] with SRNS have
shown that glomerular clearance of neutral macromolecules of
Received for publication October 10, 1988
and in revised form June 6, 1989
Accepted for publication June 15, 1989
© 1989 by the International Society of Nephrology
all sizes is diminished, despite the grossly increased clearance
of anionic proteins such as albumin. This indicates a specific
loss of charge-selective filtration with retention of size selectiv-
ity. Histochemical studies have demonstrated reduced uptake
of cationic markers by the GCW in SRNS [3, 12], puromycin
nephrosis [18], and the congenital nephrotic syndrome [191.
Enzymatic removal of heparan sulphate on the GCW [20] or its
neutralization of polycations [21—23] causes proteinuria similar
to that of SRNS, as well as diminished binding of cationic
markers to the GCW [21, 23].
We have previously reported that in addition to the proposed
defect in GCW negative charge, the surface charge of red blood
cells and platelets from children with SRNS is reduced [24],
suggesting that the disorder of membrane charge is not confined
to the kidney. Furthermore, we showed that despite the reduc-
tion of cell surface charge, as measured by the binding of the
cationic dye Alcian blue, the sialic acid content of the red blood
cells was normal [24]. As sialic acid is responsible for most of
the negative charge on red blood cells [25], the findings indi-
cated that the charged groups were masked or neutralized
rather than quantitatively deficient. We therefore postulated
that the reduction in glomerular, red blood cell, and platelet
negative charge in SRNS might be due to the presence of a
factor which binds to and neutralizes charged groups on cell and
membrane surfaces [24].
In this paper, we present evidence that plasma and urine from
children with SRNS, but not from normal children, contains a
highly cationic protein, which binds to and neutralizes the
charge on glycosaminoglycans (GAGs). We report some of the
physicochemical properties of this protein and describe a pro-
cedure for its partial purification from SRNS plasma and urine.
Methods
Patients and samples
SRNS was diagnosed by standard clinical criteria [26] in
children admitted to the Renal Unit at the Hospital for Sick
Children, Great Ormond Street, London. Renal biopsy was not
performed in most cases, minimal change histology being
inferred from the typical clinical and laboratory features and the
presence of a relapsing nephrotic syndrome responsive to
corticosteroids. Renal biopsy was always undertaken in pa-
tients whose clinical features were atypical and in those with
poorly selective proteinuria or inadequate response to steroids.
Patients were considered to be in relapse if their urine contained
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3+ protein (Albustix) for three consecutive days. Healthy adult
hospital or laboratory staff were studied as controls.
Venous blood was collected with informed parental consent
from SRNS children in relapse and controls, into plastic tubes
containing one-tenth volume of 3.8% (wt/vol) trisodium citrate.
Plasma was prepared by centrilugation at 1,300 g for 15 minutes
and stored at —70°C until required. Urine was collected into
plastic bottles without preservative and kept frozen at —20°C.
Continuous urine collections were undertaken for two to three
days following diagnosis of SRNS relapse, or until proteinuria
declined below 3+. Urine collections were obtained both before
and after initiation of steroid treatment.
Materials
The following reagents were obtained from Pharmacia Ltd.
(Milton Keynes, UK): DEAE Sephacel; heparin Sepharose;
QAE Sephadex A50; Sephadex G150; Sephadex G100; Mono-S
FPLC columns; Blue Dextran; bovine serum albumin; and
ribonuclease A. Hemodialysis filters were obtained from Gam-
bro Ltd. (Sidcup, UK). Alcian blue 8GX was from Imperial
Chemical Industries or was purchased from BDH Chemicals
Ltd. (Poole, UK; batch no. 45038106G). Heparin BP was
obtained from Paines and Byrne Ltd. (London, UK). Protamine
sulphate was purchased from Weddel Pharmaceuticals Ltd.
(Wrexham, UK). Poly-l-lysine, lysozyme, pronase, and sodium
dodecyl sulphate (SDS) were obtained from Sigma Chemicals
(Poole, UK). Platelet factor 4 and beta thromboglobulin were
from Dr. Joan Dawes at the Medical Research Council Immu-
noassay Laboratory (Edinburgh, Scotland, UK).
Detection of charge-neutralizing factors
As the only initially predicted property of the charge-neutral-
izing factor was that it would bind to and neutralize the negative
charge on cells and membranes, we made use of this property
for its detection. The anionic GAGs heparin, heparan sulphate,
chondroitin sulphate, and dermatan sulphate are among the
most anionic constituents of biological membranes [27, 28], and
are also present in plasma [291 and urine [30]. Most methods for
detection of GAGs utilize their negative charge and involve
precipitation of GAGs from solution by cationic dyes or deter-
gents [30—32]. We used the method of Whiteman [30, 33], in
which the cationic dye Alcian blue 8GX is used to precipitate
GAGs from plasma and urine. On mixing Alcian blue with
GAGs in solution, a precipitate is formed which at pH 5.8 in the
presence of magnesium chloride is specific for GAGs [30, 331.
The Alcian blue in the precipitate can be quantified after
solubilization in SDS, by measurement of the optical density at
678 nm. The concentration of GAGs in the original solution is
then calculated by reference to the Alcian blue precipitate
formed using a standard GAG solution.
Although this method is largely unaffected by normal plasma
or urine proteins [30, 33], highly cationic proteins such as
protamine or polylysine, which bind to GAGs with high affinity,
would be expected to resist displacement by Alcian blue. The
presence of protamine or protamine-like cationic factors might,
therefore, be inferred by their ability to inhibit the binding of
Alcian blue to GAGs.
To confirm that highly cationic proteins could be detected by
their ability to interfere with the binding of Alcian blue to
GAGs, the amount of Alcian blue precipitated was determined
Heparin, units
Fig. 1. Precipitation of Alcian blue-heparin complexes in the presence
and absence of protamine sulphate. Known concentrations of heparin
were incubated with a solution of Alcian blue as described in Methods.
The optical density at 678 nm of the resulting Alcian blue precipitate
was linearly related to the amount of heparin present (dots). In the
presence of protamine sulphate, the precipitation of Heparin-Alcian
blue complexes was greatly diminished (open circles).
for standard GAG solutions (heparin 0 to 40 U/ml in distilled
water) in the presence and absence of protamine sulphate 2
mg/ml. One hundred microliters of the heparin solution or the
heparin/protamine mixture was added to 2 ml Alcian blue
solution (0.05% wt/vol Alcian blue 8GX in 50 m sodium
acetate buffer pH 5.8 containing 50 ma MgCI2). After incuba-
tion at room temperature for three hours, the precipitate was
recovered by centrifugation at 2,000 g for 15 minutes. The
precipitate was washed once in 2 ml ethanol and again centri-
fuged. After decantation of the ethanol, the precipitate was
dissolved in 1 ml 7.5% (wt/vol) sodium dodecyl sulphate (SDS)
and the optical density (OD) at 678 nm recorded. The resulting
standard curve of the Alcian blue precipitate obtained with
different concentrations of heparin, in the presence or absence
of protamine was included as a control in all subsequent
experiments (Fig. 1).
To establish the range of concentrations of cationic proteins
which would interfere with the precipitation of heparin by
Alcian blue, and therefore be detected by this method, increas-
ing concentrations of known heparin binding or cationic pro-
teins (protamine sulphate; poly-l-lysine; lysozyme; platelet fac-
tor 4; and beta thromboglobulin) dissolved in 250 .d water were
incubated for 30 minutes with a standard solution of heparin (20
units in 250 jil water). One hundred microliters of the mixture
was then removed, and added to the Alcian blue solution. The
Alcian blue-heparin precipitate was recovered by centrifuga-
tion, solubilized in SDS, and quantified by measuring the
optical density at 678 nm. The percentage inhibition of Alcian
blue binding to heparin by the test substance, henceforth
referred to as the hepann neutralizing activity, was calculated as:
% heparin neutralization (heparin neutralizing activity) =
—
OD of Alcian blue + heparin standard + test substance
OD of Alcian blue + heparin standard
x 100
0
3
2
0
10 20 30 40
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Samples were considered to contain heparin neutralizing activ-
ity if greater than 10% heparin neutralization was observed on
duplicate tests.
The presence of cationic proteins in fractions of plasma or
urine was detected by adding 250 pi of the sample to be tested
to an equal volume of solution containing 20 units of heparin,
and determining the heparin neutralizing activity of the sample
exactly as described above. Fractions of SRNS plasma or urine
were tested concurrently with similar fractions of plasma and
urine from healthy individuals. All samples were dialyzed
against 0.01 M ammonium acetate buffer pH 7.0 (hereafter
referred to as test buffer) prior to incubation with heparin to
avoid interference from electrolytes known to alter the binding
of polycations to GAG [30, 331.
Fractionation of plasma and urine
All procedures were performed in the cold at 0 to 4°C. Prior
to fractionation, plasma was clotted by addition of CaCl2 and
the fibrin removed by centrifugation. Urine was pooled in
batches of 5 to 20 liters and dialyzed against deionized water
using a Gambro hemodialysis membrane. The urine was then
concentrated to approximately 1 liter volume by positive pres-
sure ultrafiltration on the same membrane. The concentrated
urine was lyophilized and stored until required.
DEAE-Sephacel ion-exchange chromatography. Pooled defi-
brinated plasma (80 ml) from SRNS children or adult controls
was dialyzed against 0.01 M potassium phosphate buffer pH 7.7
and applied to a column of DEAE-Sephacel (2.6 x 90 cm)
equilibrated in the same buffer, The column was washed
extensively with buffer and the bound fractions then eluted with
a linear gradient of 0 to I M NaC1 in the same buffer. The
column was loaded at a flow rate of 40 rnl/hr, and 15 minute
fractions were collected. Column runs were monitored for
proteins at an optical density of 280 nm using a Pharmacia UV- 1
monitor. Collected fractions were pooled in groups of 10, and
concentrated either by dialysis in Visking tubing against poly-
ethylene glycol (molecular weight 6,000 daltons) or by iyo-
philization. After reconstitution to 5 ml volume and dialysis
against test buffer; fractions were tested for heparin neutralizing
activity.
Pooled, dialyzed, and lyophilized urine from SRNS children
or controls (initial volume, 3 liters) was reconstituted in 100 ml
of 0.01 M potassium phosphate buffer pH 7.7. After separation
on a DEAE-Sephacel column under the same conditions as
described above, the heparin neutralizing activity of the frac-
tions was determined.
Heparin sepharose chromatography. Pooled, defibrinated
plasma (80 ml) from SRNS children or controls was dialyzed
against 0.1 M acetic acid and the pH adjusted to 7.0 by addition
of NH4OH. The ionic strength was adjusted to 10 pSi by
dilution with deionized water and the plasma was then applied
at 40 mllhr to a column of heparin Sepharose (80 x 2.6 cm)
previously equilibrated with the same buffer. The column was
washed with the start buffer and then eluted with a gradient of
0 to 3 M NaCl in the same ammonium acetate buffer. Ten ml
fractions were collected, pooled in groups of ten, dialyzed to
remove NaCl, and then lyophilized. The residue was then
reconstituted in test buffer and the heparin neutralizing activity
determined.
Lyophilized urine (2 to 10 liters starting volume) from SRNS
children or controls was dissolved in 0.1 M acetic acid and the
pH adjusted to 7 by addition of NH4OH. After adjusting the
ionic strength to 10 pSi by dilution with deionized water, the
urine was fractionated on a heparin Sepharose column under
the same conditions as described for plasma.
Repeat heparin Sepharose chromatography. Fractions of
SRNS urine, which were bound to heparin Sepharose and
eluted with the NaCl gradient, were pooled, dialyzed against 0.1
M acetic acid ammonium acetate buffer pH 7.0 and after
adjusting the ionic strength to 10 pSi, re-applied to the heparin
Sepharose column under the same conditions as used previ-
ously. The bound fractions were eluted stepwise with increas-
ing concentrations of NaCI (35, 75, and 150 pSi) in the same pH
7.0 buffer. The fractions eluting in each step were pooled,
dialy d to remove NaC1, lyophilized and reconstituted in 5 ml
test buffer before assay for heparin neutralizing activity.
QAE Sephadex ion-exchange chromatography: batch ab-
sorption. Pooled, defibrinated plasma (100 ml) from SRNS
children or controls was dialyzed against 0.1 M acetic acid with
the pH adjusted to 9.0 by addition of NH4OH. The plasma was
then diluted to ionic strength 3 pSi and mixed overnight with 1
liter of swollen QAE Sephadex A50 beads previously equili-
brated in the same buffer. The beads were then poured into a
Buchner funnel and the unbound fraction eluted by washing the
beads with 5 liters of the same pH 9 buffer. The bound fractions
were then eluted stepwise with 5 liter volumes of ammonium
acetate buffer (ionic strength 3 pSi) pH 8.0 and pH 7.0, and
finally pH 7.0 buffer containing 2 M NaCl. The fractions eluting
in each step were lyophilized, reconstituted in 10 ml test buffer,
dialyzed against the same buffer, and tested for heparin neu-
tralizing activity.
Lyophilized urine (5 to 20 liters starting volume) from SRNS
children or controls were dissolved in pH 9.0 ammonium
acetate buffer (ionic strength 3 pSi) and batch chromatographed
on QAE Sephadex under the same conditions as for plasma.
Column chromatography. Material eluting at pH 9.0 from the
QAE Sephadex batch absorption step was dialyzed against the
same pH 9.0 ammonium acetate buffer and then applied to a
column (2.6 x 90 cm) of QAE Sephadex A50 previously
equilibrated with the same buffer. The column was washed with
pH 9.0 buffer until the unbound fraction had eluted, and then
successively with ammonium acetate buffer pH 8.0 and pH 7.0,
and then pH 7 buffer containing 2 M NaC1. The fraction eluting
in each step was lyophilized, reconstituted in 10 ml test buffer,
dialyzed against the same buffer, and tested for heparin neu-
tralizing activity.
Ge/filtration on Sephadex G100 and G150. Five ml volumes
of the fraction eluting at pH 9 from the QAE Sephadex column,
which contained the heparin neutralizing activity, were dia-
lyzed against 1 N acetic acid pH 3.5 containing 2 M NaC1, and
chromatographed on either Sephadex GlOO or Sephadex G150
previously equilibrated in the same buffer. The columns (2.6 x
90 cm) were loaded and eluted at a flow rate of 12 mllhr, and 15
minute fractions were collected. Protein peaks were pooled,
dialyzed against 0.01 M acetic acid buffer pH 3.5 to remove
NaCl, and lyophilized. The fractions were reconstituted in 5 nil
test buffer and the heparin neutralizing activity determined.
Columns were calibrated using Blue Dextran 2,000; IgG
(150,000 daltons); bovine serum albumin (67,000 daltons); chy-
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motrypsinogen A (25,000 daltons); and ribonuclease A (13,700
daltons) as molecular weight markers.
Fast protein liquid chromatography on Mono-S. Two ml
fractions containing heparin neutralizing activity from either the
QAE Sephadex column step or the Sephadex G150 gel filtration
step were dialyzed against 100 m sodium citrate buffer pH 3.5,
diluted to 10 ml in the same buffer, and loaded using a 10 ml
superloop applicator onto a 1 ml column of Mono-S beads. The
column was washed with 20 ml of the same buffer, and then
eluted with a linear gradient of 0 to 100% sodium citrate buffer
pH 3.5 containing 2 M NaCl. Two ml fractions were collected,
dialyzed against test buffer, and the heparin neutralizing activ-
ity of the entire 2 ml volume determined.
Pronase digestion of fractions containing heparin neutraliz-
ing activity. Fractions of SRNS plasma and urine (250 d) were
tested for heparin neutralizing activity after incubation with
pronase (1 mg/ml final concentration) in 100 s1 test buffer, or
with test buffer alone. As a control, the hepann neutralizing
activity of protamine sulphate was determined with and without
pronase digestion.
Results
Detection of heparin neutralizing activity using known
proteins
On incubation of increasing concentrations of heparin with
Alcian blue solution, there was a linear increase in the amount
of Alcian blue precipitated (Fig. 1). Preincubation of the heparin
with protamine sulphate (2 mg/mi) greatly diminished the
amount of Alcian blue precipitated (Fig. 1). The highly cationic
proteins protamine sulphate and poly-l-lysine induced a con-
centration dependent inhibition of the precipitation of heparin
by Alcian blue (Fig. 2). Heparin neutralizing activity was
detected in concentrations of protamine or polylysine as low as
0.002 mg/mi, and was maximal in concentrations above 1
mglml. In contrast to the potent effect of protamine and
polylysine, platelet factor 4, beta thromboglobulin and lyso-
zyme had little hepann neutralizing activity. Even in concen-
trations above 2 mg/mi, they produced less than 20% inhibition
of Alcian blue precipitation by heparin (Fig. 2).
Heparin neutralizing activity of fractions of SRNS or normal
plasma and urine
DEAE-Sephacel ion-exchange chromatography. Initial frac-
tionation of SRNS or control plasma and urine was performed
on DEAE-Sephacel to obtain a cationic fraction (passing un-
bound through the column) and an anionic fraction (eluting with
the NaC1 gradient). The procedure also separated most of the
endogenous GAGs (which bound to the DEAE-Sephacel at low
ionic strengths) from the cationic fractions. As shown in Figure
3, heparin neutralizing activity was not detected in the cationic
fractions of normal plasma (Fig. 3A), whereas heparin neutral-
izing activity was present in the unbound fractions of SRNS
plasma (Fig. 3B), The heparin neutralizing activity did not elute
as a discrete peak, but was present as a diffuse zone in fractions
overlapping the initial IgG peak.
Heparin neutralizing activity was also present in the unbound
fractions of nephrotic urine (Fig. 3C), but was not detected in
fractions of control urine (data not shown). The results were
0.0001 0.001 0.01 0.1 1.0 10
Concentration of competitor, mg/mi
Fig. 2. Heparin neutralizing activity of polycations. Increasing con-
centrations of protamine sulphate (open circles) or poly-1-lysine (open
triangles) in 250 0 water were added to an equal volume of solution
containing 20 units of heparin, and hepann neutralizing activity deter-
mined as described in Methods. Whereas protamine and polylysine
inhibited the binding of Alcian blue to heparin even in very low
concentrations, the weaker cationic or heparin binding proteins, lyso-
zyme (open square), beta thromboglobulin (solid triangle), or platelet
factor 4 (solid square) had minimal heparin neutralizing activity even in
high concentrations.
reproducible on duplicate column runs using plasma or urine
pooled from different patients.
Heparin Sepharose chromatography. Fractionation of nor-
mal or SRNS plasma on heparin Sepharose is shown in Figure
4. Heparin neutralizing activity was not detected in fractions of
normal control plasma (Fig. 4A), but was found in the fractions
of SRNS plasma which were bound to the column and eluted
with the NaC1 gradient (Fig. 4B).
Heparin neutralizing activity was not detected in any fraction
of normal control urine fractionated on heparin Sepharose (Fig.
5A), whereas several of the bound fractions of SRNS urine
contained heparin neutralizing activity (Fig. 5B). Similar results
were obtained on repeated column runs using plasma or urine
pooled from different patients.
As was observed on fractionation of SRNS plasma or urine
on DEAE-Sephacel, the heparin neutralizing activity did not
elute from heparin Sepharose as a discrete peak but was found
in several zones eluting at ionic strengths between 10 sSi and 60
psi. In order to exclude column overload as the cause of this
non-discrete elution, the bound fractions were rechromato-
graphed on the same column using stepwise elution. As shown
in Figure 6, several peaks of heparin neutralizing activity were
again obtained, eluting at ionic strengths between 10 Si and
150 jsSi.
QAE Sephadex ion-exchange chromatography. In order to
obtain sufficient quantities of the heparin neutralizing material
to process through several steps of a purification process, an
initial batch fractionation procedure on QAE Sephadex was
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used. The fractionation was carried out at pH 9.0, as at this pH
most of the contaminating plasma and urine proteins would be
above their iso-electric point and would bind to the QAE
Sephadex. Heparin neutralizing activity was not detected in the
unbound fractions of normal plasma or urine, eluting at pH 9.0.
In contrast, heparin neutralizing activity was found in the
unbound pH 9.0 fractions of SRNS plasma and urine. Addi-
tional heparin neutralizing activity was also recovered on
washing the QAE Sephadex with pH 8.0 buffer.
The unbound pH 9.0 fraction of SRNS plasma or urine was
then rechromatographed on a QAE Sephadex A50 column (Fig.
7). The heparin neutralizing activity was detected in fractions
passing unbound through the column at pH 9.0, and some
additional activity was recovered when the column was washed
with pH 8.0 buffer.
Ge/filtration. The active heparin neutralizing fractions from
the QAE Sephadex column step were further purified on either
Sephadex GIQO or Sephadex G150. Despite the use of dissoci-
ating conditions (1 N acetic acid and 2 M NaCI) to prevent
aggregation and adherence of the proteins within the column,
the heparin neutralizing activity eluted with the void volume
and with most of the proteins on Sephadex Gl00 (data not
shown) and also eluted overlapping the Blue Dextran peak on
Sephadex Gl50 (Fig. 8). The apparently high molecular weight
of the heparin neutralizing factor may be the result of the
formation of aggregates or complexes despite the dissociating
conditions employed rather than a true reflection of molecular
size. The gel filtration step did, however, result in further
separation of the activity from contaminating proteins.
Fast protein liquid chromatography (FPLC). Fractions con-
taining heparin neutralizing activity from either the QAE Seph-
adex column step or the G150 gel filtration step were fraction-
ated on the FPLC Mono-S column (Fig. 9). A single peak of
heparin neutralizing activity was detected in fractions eluting at
60 to 75% of the NaCl gradient. The results were reproducible
in repeated column runs using material from either the Sepha-
dcx G150 or QAE Sephadex step.
Pronase digestion
Proteolytic digestion of the fractions containing heparin neu-
tralizing activity with pronase reduced the heparin neutralizing
activity (Table 1). Similar treatment of protamine also reduced
its heparin neutralizing activity.
Reproducibility
Detection of heparin neutralizing activity in fractions of
plasma or urine was reproducible in 12 of 12 fractionations
undertaken using SRNS plasma and 22 of 27 fractionations
using SRNS urine. Heparin neutralizing activity was not de-
tected in any of 10 fractionations undertaken with normal
plasma, nor in 11 with normal urine.
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Fig. 3. Ion exchange chromatography on DEAE-Sephacel of normal
plasma (A), SRNS plasma (B), or SRNS urine (C). Heparin
neutralizing activity (hatched area) was not detected in fractions of
normal plasma, but was present as a broad band of activity in the
unbound fractions of SRNS plasma and urine. Protein concentration
(OD 280 nm) is indicated by large circles, and conductivity (pSi) by
the small circles.
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Discussion
The evidence implicating loss of glomerular capillary wall
negative charge in the pathogenesis of the SRNS has been
reviewed in the introduction of this paper [1, 2, 16—23]. The
observation that surface negative charge on red blood cells and
platelets is also reduced in SRNS, despite the normal concen-
trations of sialic acid on the cell membranes [24], suggested to
us that a common mechanism may underlie the abnormal
surface charge of both blood cells and the glomerular capillary
wall. We, therefore, postulated that both phenomena might be
due to the presence of a cationic factor, which binds to and
neutralizes the surface charge on red blood cells, platelets, and
the glomerular capillary wall. To detect this postulated factor
a .2
a)V CCCo0€,,
a.
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and to isolate it from blood or urine, we have used a chemical
assay based on inhibition of binding of the cationic dye Alcian
blue 8GX to the anionic GAG heparin. The method has been
shown to detect highly cationic proteins such as protamine and
polylysine, but not weaker heparin binding proteins such as
platelet factor IV, beta thromboglobulin, or lysozyme. The
method would, therefore, be expected to detect protamine-like
factors which bind to heparin sufficiently tightly to resist
displacement by Alcian blue.
Using this method to detect charge neutralizing proteins, we
have shown that plasma and urine from children with SRNS
contains a factor which mimics the effect of protamine in
reducing the binding of Alcian blue to heparin. This factor
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Fig. 4. Heparin Sepharose chromatography
of normal plasma (A) and SRNS plasma (B).
Heparin neutralizing activity (hatched area)
was less than 10% in all fractions of normal
plasma, but was present in fractions of SRNS
plasma eluting with the NaCl gradient. Protein
concentration (OD 280 nm) is indicated by the
large circles, and conductivity (jsSi) by the
small circles.
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Fig. 5. Heparin Sepharose chromatography
ofnormal urine (A) and SRNS urine (B).
Heparin neutralizing activity (hatched area)
was not present in any fraction of normal
urine, but was present in several fractions of
SRNS urine. Protein concentration (OD 280
nm) is indicated by the large circles, and
conductivity (jsSi) by the small circles.
appears to be a protein, as its activity is lost following digestion
with pronase. The heparin neutralizing protein passes unbound
through the anion exchange medium DEAE-Sephacel at pH 7.7,
and does not bind to QAE Sephadex at pH 9.0, suggesting that
it has an iso-electric point above pH 9.0. The protein binds with
high affinity to the cation binding Mono-S ion-exchange medium
at pH 3.5, confirming its highly cationic nature. As would be
expected from its binding to heparin, the factor also binds to
heparin Sepharose at pH 7.0.
On gel filtration of the heparin neutralizing factor on either
Sephadex G100 or Sephadex 0150 in dissociating conditions,
the activity eluted with the void volume. Other highly cationic
or heparin binding proteins, such as platelet-derived growth
factor and platelet factor IV, are known to form aggregates or
complexes with other proteins and to elute from gel filtration
columns with falsely-elevated apparent molecular size [34, 35].
It is thus not clear whether the relatively-high molecular weight
of the heparin neutralizing factor we have observed is a true
reflection of its size, or the result of aggregation or complex
formation despite the use of dissociating conditions.
Purification of the heparin neutralizing protein has presented
formidable difficulties. The protein appears to be present in
very small quantities in plasma and urine, in the presence of
large quantities of contaminating proteins. Heparin neutralizing
activity cannot be detected in unconcentrated and unfraction-
ated plasma and urine, due to the presence of endogenous
glycosaminoglycans, which interfere with the Alcian blue bind-
ing assay. Initial ion exchange chromatography of large pools of
plasma or urine is necessary to remove most of the endogenous
glycosaminoglycans and to concentrate the cationic protein
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Fig. 6. Repeat chromatography of SRNS
urine on heparin Sepharose. Heparin
neutralizing activity (hatched area) was
detected in fractions eluting between 10 and
150 sSi ionic strength. Protein concentration
(OD 280 nm) is indicated by open circles.
Fig. 7. Ion exchange chromatography of
SRNS urine on QAE Sephadex A50. Heparin
neutralizing activity (hatched area) was
detected in the fraction eluting at pH 9.0. A
smaller amount of activity was also present in
the pH 8.0 fraction. Protein concentration
(OD 280 nm) is indicated by open circles.
before it can be detected. As the protein cannot be detected in
unfractionated plasma or urine, precise estimates of the recov-
ery of activity during the purification are not possible. Further-
more, the heparin neutralizing protein appears to bind readily to
GAGs and other anionic plasma constituents, forming com-
plexes of different charge and size. This results in non-discrete
elution from ion-exchange media, and may explain the rela-
tively high molecular weight on gel filtration. Highly cationic
proteins would also be likely to bind to chromatographic
columns, dialysis membranes, and plastic or glass containers,
and we suspect that considerable loss of activity occurred on
this basis during each fractionation step, resulting in very low
final yields of the active protein.
Despite these difficulties, the sequence of fractionation pro-
cedures we have employed (QAE Sephadex batch ion-ex-
change, QAE Sephadex column ion-exchange chromatography,
gel filtration on Sephadex G150, and finally FPLC on Mono-S)
has enabled us to obtain the heparin neutralizing activity in
partially purified form separated from many grams of protein in
the original plasma or urine. Although the activity elutes as a
single peak from the Mono-S FPLC step containing less than 1
mg of protein, several protein bands are still visible at this stage
on SDS polyacrylamide gel electrophoresis. It is not yet clear
whether the multiple bands are due to the presence of contam-
inating proteins not removed by the purification procedure, or
whether the heparin neutralizing activity is composed of more
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Fig. 8. Gel filtration of SRNS urine fractions
on Sephadex G150. Hepann neutralizing
activity (hatched area) was detected in
fraction 32-60. The arrows indicate the elution
position of the molecular weight markers,
Blue Dextran (A), IgG (molecular wt 150,000
daltons) (B), bovine serum albumin (67,000
daltons) (C), and ribonuclease A (13,700
daltons) (D). Protein profile (OD 280 nm) is
shown by circles.
Fig. 9. Fast protein liquid chromatography of
SRNS urine fractions on Mono-S. Heparin
neutralizing activity (hatched area) was
detected in fractions 20 and 21. The solid line
indicates the OD 280 nm tracing from the
column recorder. Circles indicate percent of
NaC1 gradient.
than one protein. Further steps are thus required to complete
the purification of the protein.
Although it is possible that the cationic protein(s) we have
detected in plasma and urine of children with SRNS are present
as a secondary consequence of the heavy proteinuria, several
lines of evidence suggest that this protein may be pathogenic
rather than simply a consequence of the derangement of plasma
and urinary proteins of the SRNS. Infusion of protamine or
other highly cationic proteins into the kidney of experimental
animals induces proteinuria selective for albumin [2 1—231, as
well as diminished uptake of cationic dyes on the glomerular
capillary wall [21, 23]. Furthermore, infusion of protamine into
the systemic circulation of anephric rats produces a generalized
increase in capillary permeability [36]. Cationic proteins such as
polylysine have also been shown to bind to platelets and red
blood cells, and to induce platelet aggregation and diminished
binding of cationic markers to cell membranes [37] similar to
that observed in SRNS [24, 38]. It, therefore, seems likely that
Table 1. Heparin neutralizing activity after pronase digestion
Fraction
% Heparin neutralizing
activity
Without With
pronase pronase
SRNS Urine pH 9.0 QAE
Sephadex Fraction
SRNS Plasma pH 9.0 QAE
Sephadex Fraction
SRNS Urine pH 8.0 QAE
Sephadex Fraction
Protamine sulphate 1 mg/mI
Protamine sulphate 0.1 mg/mI
33 0
42 9
15 0
80 52
58 0
Fractions of SRNS plasma or urine prepared by QAE Sephadex
column ion exchange chromatography were tested for heparin neutral-
izing activity after incubation for 1 hr at 37°C with pronase (final
concentration I mg/mi) in test buffer, or with test buffer alone. Heparin
neutralizing activity was diminished by pronase treatment. Pronase
digestion of protamine sulphate also reduced heparin neutralizing
activity.
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a highly cationic protein such as we have detected in SRNS
plasma, which binds to heparin and resists displacement by
Alcian blue, would also bind to the heparin sulphate on the
glomerular capillary wall, and thus reduce the surface negative
charge responsible for restricting the filtration of albumin and
other anionic proteins. Confirmation of a pathogenic role for the
heparin neutralizing protein must await completion of its puri-
fication and demonstration that it is deposited on the glomerular
wall.
It is of interest that Staprans et al, studying the lipoprotein
lipase activating GAGs in SRNS urine, noted that GAGs in
SRNS urine were complexed to a protein which caused abnor-
mal electrophoretic mobility and abnormal chromatographic
behavior of the GAGs [39]. It is possible that the protein in the
GAG-protein complex documented by these workers is the
same cationic heparin binding protein we have detected. Fur-
thermore, in vitro studies of the anticoagulant effect of heparin
in SRNS plasma have shown diminished heparin activity [401.
Although several other factors might be involved in the reduced
anticoagulant effect of heparin, binding to a protamine-like
cationic protein might also be contributory.
If the charge-neutralizing protein we have detected and
partially purified is indeed responsible for the neutralization of
glomerular capillary wall negative charge, and thus the protein-
uria of the SRNS, a key question is its origin and the reason for
its presence in the circulating blood. Several cells of the
immune system are known to contain highly cationic proteins,
which are released during activation. These proteins include
neutrophil cationic proteins [41], eosinophil basic proteins [421,
macrophage cationic proteins [43], and platelet cationic pro-
teins [44]. These proteins are known to have a variety of
biological activities and may increase vascular permeability [42,
44, 45], neutralize heparin [42], induce histamine release [44],
stimulate chemotaxis [46], and kill bacteria [47]. Neutrophil and
platelet-derived cationic proteins have also been shown to bind
to the glomerular polyanion [48, 49], and may reduce the fixed
negative charge on the glomerular capillary wall [49].
The SRNS is often precipitated by upper respiratory tract
infections or allergic insults [50]. Moreover, the response to
steroids, immunosuppressive drugs and natural measles suggest
that the disorder may have an immune mediated pathogenesis
[51, 52]. It is, therefore, possible that the charge-neutralizing
cationic protein is released from some cell of the immune
system during immune activation.
Although we have so far only studied patients with SRNS,
there is evidence that release of cationic proteins which bind to
and neutralize the charge on the GCW may also occur in other
forms of experimental or human nephritis [49, 53, 54]. Camussi
et al have documented deposition of neutrophil-derived cationic
proteins in glomeruli of patients with the nephrotic syndrome
due to systemic lupus erythematosus [53], and both neutrophil
and platelet derived cationic proteins have been shown to be
deposited in the glomeruli during some forms of experimentally
induced inflammation [49, 54]. A variety of different cationic
proteins may be released from inflammatory cells and deposited
on the glomerular capillary wall in different forms of nephritis.
The Alcian blue inhibition assay we have utilized will detect any
highly cationic protein which binds to heparin sufficiently
strongly to resist displacement by Alcian blue. It therefore
cannot be used to establish whether the cationic protein we
have detected in SRNS is unique to this disorder, or one which
may also play a role in the pathogenesis of other forms of
nephrotic syndrome. Development of a more specific, immuno-
logically based assay to detect the heparin binding cationic
protein in SRNS will be necessary to establish whether this
protein is unique to SRNS, and to confirm that the protein is
deposited on the glomerular capillary wall.
We conclude by postulating that the basic defect in SRNS
may be an excessive or uncontrolled release of cationic proteins
from some cellular component of the immune or acute phase
response system. The effect of steroids and immunosuppression
may be to reduce the release of these proteins.
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